Adaptogenics names peptide chemist J. David Warren chief executive
Warren, whose mechanistic work underpinned SS-31, will steer the CSE-listed company toward peptide and small-molecule candidates in metabolism and mitochondrial biology.
TR
By Tom Reyes · Markets Editor
Oct 2 07:45 ETSource: The Globe and Mail
The wire
- 01Adaptogenics Health Corp. (CSE: ADPT) appointed J. David Warren, Ph.D., as CEO and director effective Oct. 1, 2026, with Gurinder Sandhu named EVP, corporate development.
- 02Warren's published work includes foundational mechanistic research on SS-31, now elamipretide, which won FDA accelerated approval as Forzinity for Barth syndrome in September 2025.
- 03The company says initial evaluation areas include metabolic function, muscle preservation during weight loss, mitochondrial biology and inflammation resolution; no named assets were disclosed.
From the source
Read at theglobeandmail.comAdaptogenics Appoints Accomplished Peptide Scientist Dr. J. David Warren as Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics" or the "Company") is pleased to announce the appointment of J. David Warren, Ph.D., as Chief Executive Officer and as a director of the Company, effective October 1 st , 2026.
